How is the CRISPR Therapeutics AG today?

The CRISPR Therapeutics AG today is trading in the green, up by 1.40% at 36.10.

How has CRISPR Therapeutics AG performed historically?

The CRISPR Therapeutics AG is currently trading up 1.40% on an intraday basis in the past week the index rose 5.40%. The index has been down -27.39% in the past quarter and fell -35.20% in the past year. You can view this in the overview section.

What is CRISPR Therapeutics AG Annual Revenue?

CRISPR Therapeutics AG Annual Revenue fell 90.54%, in the last year to $35 M. Its sector's average revenue growth for the last fiscal year was 8.41%.

What is CRISPR Therapeutics AG Annual Net Profit?

CRISPR Therapeutics AG Annual Net Profit fell 138.43% in the last year to $366.25 M. Its sector's average net profit growth for the last fiscal year was -12.47%.

What is CRISPR Therapeutics AG Price to Earning Ratio?

CRISPR Therapeutics AG Price to Earning Ratio is -8.08, which is negative.

What is CRISPR Therapeutics AG Stock Price?

CRISPR Therapeutics AG Stock Price fell 35.2% and underperformed its sector by 44.28% in the past year.

What is CRISPR Therapeutics AG Quarterly Net profit?

CRISPR Therapeutics AG Quarterly Net profit fell 16.64% YoY to $136 M. Its sector's average net profit growth YoY for the quarter was -402.06%.

What is CRISPR Therapeutics AG Debt to Equity Ratio?

CRISPR Therapeutics AG Debt to Equity Ratio of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is CRISPR Therapeutics AG Return on Equity(ROE)?

CRISPR Therapeutics AG Return on Equity(ROE) for the last financial year was -19.2%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is CRISPR Therapeutics AG Mutual Fund Holding?

CRISPR Therapeutics AG Mutual Fund Holding decreased by 5.6% in the last quarter to 63.45.

What is CRISPR Therapeutics AG Promoter Share Holding?

CRISPR Therapeutics AG Promoter Share Holding increased by 0.05% in the most recent quarter to 0.5%.

What is CRISPR Therapeutics AG Institutional Holding?

CRISPR Therapeutics AG Institutional Holding decreased by 0.24% in the last quarter to 76.89.

CRISPR Therapeutics AG XNAS: CRSP

CRISPR Therapeutics AG Live Share Price Today, Share Analysis and Chart

Name: CRISPR Therapeutics AG: Is Infosys Ltd. worth buying?
Item: CRISPR Therapeutics AG
Rating: 0.89016675
Author: Trendlyne DVM scores

Weak Stock

about

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revol...

36.10 0.50 (1.40%)

46.82% Fall from 52W High

1.0M XNAS Volume

XNAS 15 May, 2025 3:28 PM (EDT)

Low Financial Strength

16.7 / 100

Expensive Valuation

10.5 / 100

Technically Bearish

27.4 / 100

Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 127%

24 analysts

CRISPR Therapeutics AG Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

CRISPR Therapeutics AG Live Share Price Today, Share Analysis and Chart

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revol...

46.82% Fall from 52W High

SWOT Analysis

CRISPR Therapeutics AG Live Price Chart

CRISPR Therapeutics AG FAQ

How is CRISPR Therapeutics AG today?

CRISPR Therapeutics AG today is trading in the green, and is up by 1.40% at 36.10.

How has CRISPR Therapeutics AG performed historically?

CRISPR Therapeutics AG is currently trading up 1.40% on an intraday basis. In the past week the stock rose 5.40%. stock has been down -27.39% in the past quarter and fell -35.20% in the past year. You can view this in the overview section.